Umbilical cord blood (CB) is increasingly used as an alternative source of stem cells in adult unrelated transplantation. Although registry studies report similar overall outcomes in comparison with BM/PB, comparative studies focusing on severe infections and infection-RM (IRM) with a long follow-up are scarce. A total of 434 consecutive unrelated transplants (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009) were retrospectively analyzed to compare overall outcomes, incidence and risk factors of severe viral and invasive fungal infections in CB (n = 65) vs BM/PB recipients (n = 369). The 5-year OS was 38 vs 43%, respectively (P = 0.2). CB transplantation (CBT) was associated with a higher risk of invasive aspergillosis (100-days-cumulative incidence 16 vs 6%, P = 0.04) and CMV infection without differences in RM. No statistically significant differences were found regarding NRM (NRM of 38% in CB vs 37% in BM/PB at 1 year) nor IRM (30% in CB vs 27% in BM/PB at 1 year). In the overall population, NRM and IRM improved in more recent years. In adults who receive a single CBT, the risk of severe infections is increased when compared with unrelated BM/PB recipients, but mortality from infections is similar, leading to similar NRM and survival. 
INTRODUCTION
Infections are a major concern after allo-HSCT, and the main cause of mortality in at least 35-45% of deaths. [1] [2] [3] [4] [5] [6] [7] The use of unrelated donors (UD) in adults increases the risk of severe infectious complications, although recent reports have found similar survival with matched sibling and UD allo-HSCT in the setting of specific diseases, such as AML. 8, 9 Moreover, the use of cord blood (CB) as an alternative source of HSC in adults who lack an HLA-matched UD BM or PB has shown to be a valid alternative for an allo-HSCT. Recent studies have shown that similar NRM and OS can be achieved with CB if an accurate choice of the CB unit(s) is made, in comparison with other alternative donor sources. [10] [11] [12] [13] [14] [15] However, slow hematologic and immune recovery after CB transplantation (CBT) still remains a concern, and a high rate of serious pre and post-engraftment infections has been reported. However, few studies have actually compared the incidence of severe infections and infection-RM (IRM) of adult CBT recipients as opposed to UD BMT/PBT.
For this purpose, and as a continuation of a previously published study by our group, 16 we performed a multicenter 12-year retrospective study to analyze the impact of the source of HSC for UD transplantation, including single CBT and BM/PBT on overall transplantation outcomes, especially. We also analyzed the occurrence and risk factors of CMV infections (as well as other less common viral infections) and invasive fungal infections (IFIs), especially invasive aspergillosis (IA) and the impact of stem cell source on their occurrence. We also analyzed the changes of these complications over the 12-year study period.
PATIENTS AND METHODS

Patient selection
We invited all member centers of the GETH (Spanish group of SCT) to include all consecutive adult patients (>15 years) who underwent an allo-HSCT from an UD (adult volunteer UD or single CB) from 1January 1997 to 31 March 2009. The follow-up of cases included in a previous study, which represent about 1/3 of the patients reported herein and transplanted up to early 2004 (ref. 16) , was updated and additional data was included. Finally, 10 Spanish centers agreed to participate and filled in a detailed case report form for each transplant, with special emphasis on severe viral and IFIs. The database for analysis was closed at the end of 2011, assuring a minimum follow-up of 1 year (median follow-up in survivors of 51 months, range 13-164 months). Centers who performed mostly CBT for those lacking a matched sibling, as well as those who did not perform single CBT (refs 17,18) , did not participate in the study by their own decision, this issue avoid the bias of including of centers highly specialized in one specific type of UD transplantation. Antiviral and antifungal prophylaxis (AFP) Antiviral prophylaxis consisted of low-dose acyclovir (400 mg twice a day i.v.) in 64% of BM/PB and 77% CB recipients, while high-dose acyclovir (5 mg/kg three times a day) was used in the remaining cases. Broadspectrum (other than fluconazole) AFP in the peri-transplant period (from conditioning until 100 days after SCT, unless GVHD occurred when it was usually prolonged) was used in 182 patients in total, 44.5% and 27.5% of cases of BM/PB and CB, respectively (P = 0.02); for this purpose, in BM/PB, the most frequent AFP was itraconazole (oral solution or i.v. formulation) in 52% of cases (85 out of 164 with broad -spectrum AFP) followed by posaconazole or voriconazole in 31% of cases. In CB recipients the most frequent AFP was posaconazole/voriconazole in 66.5% (12/18), followed by itraconazole in 22% (4 out of 18 with broad-spectrum AFP). Less common was the use of nebulizer amphotericin together with fluconazole (11% of cases for each group), as well as others as amphotericin or echinocandins (only 10 patients, 6%, in BM/PB group). At the time of IFI (specifically moulds) diagnosis the absolute number of patients who were receiving broad-spectrum AFP was 35 (51, 4%) vs 34 (50%, P = 0.8) out of the total 69 mould infections.
Definitions
Patients were considered to have died from an infection (that is, IRM) if death was attributed to one or more recent severe infections by the primary physicians and the coordinators of the study (R.P. and R.M.) and/or a lethal infection was identified at autopsy.
Any viral or IFI requiring i.v. treatment, or which required or prolonged hospitalization were included in the current study; in addition, all cases of CMV and EBV infection were also included in this study. Infection data were collected retrospectively by each investigator until the patient's death or last follow-up, using standardized definitions of severe infections after HSCT based on the guidelines from the Infectious Diseases Working Party of the European group for blood and marrow transplantation (https://www.ebmt. org/Contents/About-EBMT/Who-We-Are/ScientificCouncil).
In brief, the definitions for viral and IFIs included: (1) Proven and probable IFIs, following the updated 2008 criteria. 19 (2) CMV infection, defined as the presence of a single positive antigenemia (41 pp65 antigen-positive leukocyte among 200 000 cells counted per slide), or at least two consecutive positive results of a PCR test for CMV in PB. CMV disease was defined as clinical syndrome together with the demonstration of CMV in appropriate specimen from the involved tissue. 20 Other non-CMV severe viral infections considered in this study included (i) EBV infection determined by exponential increase of positive EBV PCR, with or without evidence of post-transplant lymphoproliferative disease (EBV-PTLD); (ii) disseminated VZV infection, affecting two or more skin dermatomes and/or visceral involvement; (iii) Human Herpesvirus 6 as cause of encephalitis, diagnosed by positive PCR from cerebrospinal fluid; (iv) Adenovirus (ADV) disease, diagnosed when ADV was identified in any sample by immunohistochemistry; and (v) pneumonia due to a community respiratory virus (CRV) or BK polyomavirus-related hemorrhagic cystitis, as defined by accepted criteria. [21] [22] [23] However, it has to be remarked that monitoring of ADV, Human Herpesvirus 6 and toxoplasma was not extensively used in all centers. EBV monitoring was introduced around 2005-2006. All microbiological tests for both viral and fungal etiologies (PCR, antigenemia, galactomannan) were interpreted in accordance with each center's laboratory.
The staging of GVHD followed NMDP guidelines. 24, 25 In addition, the study period was divided in two transplantation periods, 1997-2002 and 2003-2009 , to determine changes in outcome over time.
Disease phase at transplant was categorized as early (acute leukemia or poor-risk myelodysplasia in first CR, untreated good-risk myelodysplasia, first chronic-phase chronic myeloid leukemia, lymphoid malignancy in first remission and untreated aplasic anemia) or non-early (any other case not included as early). Details on the definition of reduced-intensity conditioning regimens are specified in Table 1 .
Statistical analysis
The primary endpoint of this study was IRM in adults who received an UD allo-HSCT with CB vs BM/PB. Secondary endpoints were CMV infection and disease, IFIs, IA, NRM and OS. In addition to the above-mentioned analyses, other conventional transplantation outcomes were described, such as hematopoietic recovery, cumulative incidence of acute GVHD (grades II-IV) and chronic GVHD, as seen in Table 1 .
Comparisons between groups were made using the χ 2 -test for categorical data, and the Mann-Whitney U-test or Student t-test for continuous data. Probabilities of OS were calculated using the KaplanMeier method, and unadjusted comparisons were made using the log-rank test. For outcomes with competing risks, NRM, IRM, CMV infection and disease, IFI, IA and GVHD probabilities were estimated using the cumulative incidence non-parametric estimator, and were compared using the Gray test. Adjusted effects on OS, NRM, IRM, CMV infection and disease, IFI and IA were estimated in terms of hazard ratio by Cox models. [26] [27] [28] The adjustment factors considered in the multivariable models included variables such as conditioning intensity, stem cell source, stem cell cellularity (defined below), advanced status, basal disease (acute leukemia vs others), mismatched (7/8 vs 8/8 for PB/BM and 4/6 vs 5/6 or 6/6 for CB), severe acute and/or chronic GVHD, time period of transplant, broadspectrum AFP and high-doses acyclovir. Due to co-linearity with GVHD, corticoid treatment was not included in multivariable analysis. The effect of those events that took place during the follow-up and after transplant, such as acute and chronic GVHD, CMV infection and disease were analyzed by treating their occurrence as a time-dependent covariate in Cox model.
All analyses were carried out using SPSS statistical software (version 12.0.1) except the analyses of cumulative incidence curves, which were carried out using the CMPRSK package in R 2.4.1.
Differences were considered to be statistically significant for two-sided P-valueso0.05. Confidence intervals (CI) refer to 95% boundaries.
RESULTS
Patients
Detailed characteristics concerning the patient/transplant characteristics and main outcomes in both study cohorts are shown in Table 1 . In the BM/PB group the stem cell source was BM in 139 cases and PB stem cells in 229 patients. The most relevant difference between the CB and BM/PB cohorts was the proportion of CMV seropositive recipients with a CMV seronegative donor (71% vs 38%, respectively, P = 0.001), which is the combination known to have the highest risk of developing CMV infection and disease. 29, 30 The status at transplant was non-early in 58% of patients, with a trend for a higher proportion in CB recipients (68 vs 59%, P = 0.1). Among the BM/PB recipients, 45% received a reduced-intensity conditioning regimen consisting of fludarabine in combination with BU or melphalan (detailed explanation in Table 1 ), while all CB recipients received a homogeneous conditioning regimen following GETH protocols. 17 Finally, in vivo T-cell depletion with Rabbit antithymocyte globulin was used in 100% CB vs 32% BM/PB recipients.
Hematological recovery. The median times to reach a neutrophil count of 0.5 × 10 9 /L, a monocyte count of 0.2 × 10 9 /L and a lymphocyte count of 0.2 × 10 9 /L were significantly delayed in CB vs BM/PB recipients (P o0.001 for all three comparisons), although the rate of primary graft failure was not significantly higher in the CB than in the BM/PB transplantation group (6 vs 3.3%, P = 0.2) ( Table 1) .
OS. With a median follow-up in survivors of 51 months (10-164), 37 and 53 months (P = 0.1) in the CB and BM/PB group, respectively, the 1-year (42.5 vs 52%) and 5-year (38 vs 43%) probability of OS did not differ between CB and BM/PB group, respectively (P = 0.2) (Figure 1 ). The univariate and multivariate analyses of OS are shown in Table 3 .
Non-relapse and IRM. No significant differences were found in the incidence of IRM nor overall NRM between CB and BM/PB recipients. The cumulative incidence of IRM was 14% at 100 days for both groups, while the 1-year IRM was 30% (95%CI ) vs 27% (95%CI (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) ) at 1 year, and 33% (95%CI (21-46)) vs 30% (95%CI (25-34)) at 5 years for CB and BM/PB, respectively (P = 0.4). Regarding NRM, the cumulative incidence was 23% at 100 days for both groups, 1-year NRM was 42 vs 37%, and 5-year NRM was 45 vs 43% in CB and BM/PB recipients, respectively (P = 0.6) ( Figure 2 ). The main causes of IRM are shown in Table 2 . Table 3 shows the univariate and multivariate analyses of the 5-year IRM. In the entire study group, the risk factors that remained statistically significant for IRM were severe GVHD, > 35 years of age, the presence of mismatches and not having received upfront broad-spectrum AFP (hazard ratio: 0.5 (0.3-0.9), P = 0.03). /kg frozen CD34+ cells). An optimal level of cellularity was infused in 67% and 70% of the cases in BM/PB and CB transplants, respectively (P = 0.6).
c Reduced intensity-conditionings included Fludarabine-BU or Fludarabine-Melphalan, as previously described (Martino et al. 37 ), whereas myeloablative regimens included CY combined with TBI (12-13.5 Gy) or BU (16 mg/kg oral or i.v. equivalent) total dose. A homogeneous conditioning regimen was used for all single CB transplants according to the Spanish protocol, which consisted of thiotepa (10 mg/kg), BU (12 mg/kg oral or i.v. equivalent, total dose) and either CY (120 mg/kg total dose) or fludarabine (120 mg/m 2 total dose) with rabbit thymoglobulin (6 mg/kg total dose) in all cases and GVHD pharmacoprophylaxis with CYA and mycophenolate mofetil or prednisone, as described by Sanz et al.
17,42
Severe infections after unrelated allogeneic transplantSevere fungal and viral infectious complications Invasive fungal infections (IFIs). Twenty (31%) and 67 (18%) patients in the CB and BM/PB groups developed one or more IFI (P = 0.02 for the comparison of frequencies), including probable and proven invasive mold and yeast-related infections (Table 2) . Aspergillus was the most common IFI in both study groups accounting for 75% and 80.5% of all IFIs in the CB and BM/PB group, respectively.
The cumulative incidence of IA (Figure 3a ) was significantly higher after CBT, both at 100 days (16 vs 6% in CB vs BM/PB) and at 1 year post transplant (20 vs 9.7%, respectively (P = 0.04). The median day of onset of IA was significantly earlier in the CB group. Most cases of IA, however, occurred post engraftment in both groups, and the median NC was similar (894/mm 3 and 874/mm 3 , respectively, in CB and BM/PB patients, P = 0.8) at diagnosis of IA; however, the absolute lymphocyte and monocyte counts were significantly lower in CB recipients (81 and 559 total lymphocytes/ mm 3 , P = 0.01; and 92 and 402 monocytes/mm 3 , P = 0.02, respectively). Several anti-Aspergillus-active antifungals were used either in combination or sequentially, making it impossible to assess the relative efficacy of different therapies.
Most yeast infections were caused by non-albicans Candida spp. (9/18 cases) or non-Candida yeasts (6/18 cases), and the median onset of yeast infections was also significantly earlier in CB recipients.
As shown in Table 3 , the risk factors found for IA in multivariate analysis included: prior CMV infection, grade II-IV acute GVHD, severe chronic GVHD and > 35 years of age, while the use of CB as stem cell source showed only a trend for a higher risk of IA. The upfront use of broad spectrum AFP, however, did not show a protective effect for IA.
There were no differences in attributable mortality due to IFI between CB and BM/PB recipients (30 vs 39% for all IFIs; P = 0.4; 27 and 42% for IA, P = 0.2; and 20 vs 22% for yeast infections, P = 0.9, respectively).
CMV and other viral infections CMV infection. One hundred and eighty-six patients (43%) developed CMV infection after allo-HSCT. A trend for a higher incidence of CMV infection was observed among CB recipients (cumulative incidence at 100 days: 42% (95% CI: 29.5-54.6) and at 1 year: 46% (95% CI: 32.6-58)) vs BM/PB recipients (cumulative incidence at 100 days: 31.5% (95% CI: 27-36) and at 1 year: 38% (95% CI:33-43), P = 0.1) (Figure 3b) .
Sixty-seven patients (36%) had one or more recurrent episodes of CMV infection, with a higher frequency in CB recipients (54%) vs BM/BP (32%), P = 0.01. CMV disease. CMV disease occurred in 39 patients, in 10 without a previous diagnosis of CMV infection (25.6%). No differences were found in the incidence of CMV disease between study groups (cumulative incidence 6% and 8% at 100 days and 1 year in each group, respectively). The organ involved was predominantly the lung in CB recipients (4/5, 80%), whereas in BM/PB recipients, the lung was affected in 50% and the gastrointestinal tract in 44% of the cases. Only three cases of disseminated CMV disease were reported. The mortality attributable to CMV disease was high in both groups: 5/6 (83%) CB recipients with CMV disease and 21/33 (64%) BM/PB recipients (P = 0.7).
Univariate and multivariate analyses of CMV infection and disease are shown in Table 3 . CB as stem cell source increased the risk of CMV infection (hazard ratio 1.9, 95% CI (1.02-3.9), P = 0.04), but not CMV disease. The only risk factor identified for CMV disease was a CMV seropositive recipient/seronegative donor vs other combinations, whereas there was a trend for reduction of CMV disease in patients transplanted in more recent years (2003) (2004) (2005) (2006) (2007) (2008) (2009) ).
Other life-threatening viral infections. EBV infection and disease were diagnosed more frequently in CB recipients. All cases received Rituximab as a pre-emptive or targeted treatment for EBV infection and disease, respectively. However, 9 out of the 12 cases of EBV-PTLD (5/6 and 4/6 in PB/BM and CB patients, respectively) led to the patients' death.
A low frequency of pneumonia by a community respiratory virus was reported, although this may be an underestimation since sensitive virological studies were not available in many centers during the study period. Other severe viral infections are detailed in Table 2 . Severe infections after unrelated allogeneic transplant R Parody et al transplantation, the generalization of quantitative PCR for CMV and EBV, as well as galactomannan and high-resolution computerized tomography scans for the early diagnosis of IA, the increase in reduced-intensity conditioning and the availability of voriconazole for treating IFI, especially IA. Table 4 summarizes the relevant differences in patient and transplant procedurerelated variables in these two time periods, as well as the univariate differences in the outcomes analyzed in the current study. Despite a large increase in patient age and fewer patients being in an early disease status, 100 day and 1-year NRM and IRM decreased over time. In addition, mortality in patients with IA and CMV disease also decreased. As shown in Table 3 , in multivariate analysis, the more recent time period (2003) (2004) (2005) (2006) (2007) (2008) (2009) ) showed a trend for lower 5-year IRM, lower CMV disease and improvement in OS.
CHANGES IN TRANSPLANTATION OUTCOMES AND IRM OVER TIME
DISCUSSION
In the setting of allo-HSCT from alternative donors, infectious complications still remain a significant cause of NRM, accounting for 40-50% of cases, associated or not associated with other complications. [1] [2] [3] [4] [5] 16, 31 Most studies to date describe selected homogeneous patient cohorts, some studies for only the first 100 days or first year after transplantation, and few compare IRM and severe infections between CBT and other types of alternative donors. 7, 16, 32 Despite the obvious limitations of the present multicenter and retrospective study, we specifically aimed at describing, as exactly as possible, number of risk factors for severe viral and fungal infections in all consecutive UD transplantations performed over a long period of time, without patient selection, in an effort to describe the problems faced in real clinical practice. We chose to focus on invasive fungal and severe viral infections, Klebsiella neumoniae 1 and non reported. 4 In some cases viral: ADV, 1 CMV, 6 respiratory syncytial virus (RSV) 1 and/or fungal infections (IA: 9) were also associated.
Severe infections after unrelated allogeneic transplant R Parody et al mainly those caused by CMV, since these infections remain a major problem in both CBT and UD allo-HSCT. An important observation in the current study is the increasing proportion of patients transplanted in advanced disease status (53% and 64% in 1997-2002 and 2003-2009, respectively) , which is likely to have a deleterious impact on severe infections, IRM, NRM and OS.
The results of the current study highlight the lack of significant differences at 100 days, 1 year and 5 years between CB and BM/PB recipients in IRM, which was the major endpoint of the study. However, some findings should be further discussed. For instance, the risk of CMV infection and IFIs (especially IA) were higher and occurred earlier in CB than in BM/PB recipients. However, mortality from IFIs, CMV disease and other viral infections did not differ between the two groups, suggesting that treatment of these lifethreatening opportunistic infections is effective in many cases. When analyzed by time periods that a significant increase in the incidence of both IA and CMV infections (but not CMV disease) occurred in the 2003-2009 period, while their attributable mortality decreased, as did the overall NRM and a trend was found in the IRM (see Table 4 ). The higher incidence of both IA and CMV infection can be explained by the increase in the sensitivity of the diagnostic methods over time, such as the routine monitoring of the serum galactomannan, together with fast-track high-resolution computerized tomography when needed, as well as routine screening of CMV with quantitative PCR (refs 33,34) , which is also done now for EBV in high risk patients. 35 CB recipients showed a higher risk of EBV infection and EBV-PTLD, partly explained by the systematic use of antithymocyte globulin in our CBT protocols, 18 while only 32% of BM/PB recipients received antithymocyte globulin.
Another apparently paradoxical finding was the beneficial impact of the prophylactic use of broad-spectrum antifungal drugs on Severe infections after unrelated allogeneic transplant R Parody et al lowering the IRM in univariate and multivariate analysis; surprisingly, these drugs had no impact on the risk of developing an IFI and more specifically IA. The heterogeneity in the use of several drugs (itraconazole and posaconazole leading the list in BM/PB and CB recipients, respectively) and the retrospective nature of the study make these contradictory findings of little relevance, and we were unable to analyze the impact of one antifungal drug over others. Another possibility is that patients who were able to tolerate broadspectrum antifungal drugs over many weeks may be the 'biologically fittest' patients, those who also have an inherent higher possibility of surviving. Unfortunately, we were of course unable to gain further insight into this matter.
The improvements in these outcomes over time have been previously reported. [36] [37] [38] [39] Further improvements in IRM, however, will probably require the use of adjuvant pharmacological or cellular-based therapies, which improve the long-term cellular and humoral immunities. [40] [41] The main limitations of the present study are linked to the multicenter and retrospective design, although the conditioning regimens were quite homogeneous for myeloablative and reduced-intensity conditioning recipients, while CB recipients all followed the same national protocol. 17 However, as far as we know there are no previous studies analyzing the infectious morbidity and mortality over such a long period of time (12 years) and comparing the results of different UD sources.
In conclusion, CB transplantation seems to be associated with a higher risk of fungal and severe viral infections. However, overall outcomes in terms of infection-and transplant-RM are equivalent to those of adult volunteer UD transplantation. On the other hand, the introduction of new diagnostic tests has led to an increased incidence of the major fungal and viral infections, while mortality from these infections has decreased. In spite of broader indications of allogeneic UD and CB transplantation to include older and higher risk patients, the overall NRM and the IRM have decreased over time.
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